Labcorp(US:LH) Prnewswireยท2024-06-17 12:00Core Insights - Labcorp has launched Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at enhancing the efficiency of clinical trials at investigator sites [1][2]. Group 1: Product Launch and Features - Labcorp Global Trial Connect is designed to simplify the investigator workflow, improve patient experience, and enable biopharma sponsors to expedite the market introduction of therapies [2]. - The suite includes site enablement resources to identify new study opportunities, enhance patient access and recruitment, and improve diversity in clinical trials [2]. - Supply readiness support is provided to increase study startup efficiencies, reduce trial delays, and minimize supply and kit waste [2]. - The platform facilitates site workflows by integrating sample collection and tracking data, offering visibility and actionable analytics to both sites and sponsors, and reducing errors and data revisions through eRequisition functionality [2][3]. - Study management and investigator support are available to accelerate study startup and maintain momentum with 24/7 site support and on-demand tools and training [2]. Group 2: Company Overview - Labcorp is a global leader in laboratory services, assisting healthcare professionals, pharmaceutical companies, and researchers in making informed decisions [4]. - The company employs over 67,000 individuals and operates in approximately 100 countries, supporting 84% of new drugs and therapeutic products approved by the FDA in 2023 [4]. - Labcorp has conducted more than 600 million tests for patients worldwide, showcasing its extensive capabilities in diagnostics and drug development [4].